Document Type : Research Articles
Department of Radiation Oncology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, India.
Faculty of Dental Sciences, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, India.
Department of Medical Oncology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, India.
Department of Pathology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, India.
Background: A troublesome and usually unavoidable consequence of Head and Neck chemo radiation is oral
mucositis which decreases patients’ compliance and negatively influences the outcome of therapy by increasing overall
treatment time. Currently, no single effective recommended treatment exists for this problem and a variety of supportive
care measures have been practiced with limited benefits. This study was done to evaluate the therapeutic benefit of
Placentrex in the management of oral mucositis seen in oral cancer patients undergoing treatment with concurrent
chemoradiation. Methodology: This study was carried out, as a retrospective analysis, on oral cancer patients undergoing
concurrent chemoradiation with weekly Cisplatin regimen treated between Oct 2015 and July 2017. All the patients
received 2ml of Inj Placentrex, once daily administered intramuscularly for 4 weeks, NSAIDs, topical analgesics,
and mouth wash as treatment for oral mucositis. The results were compared with a historical control group of 40 oral
cancer patients who had received treatment prior to the study period without receiving Inj Placentrex as a part of oral
mucositis management. Results: Over 60% of the patients in both groups were older than 60 years of age. Buccal
mucosa was the predominant sub site of the investigated cancer type. The addition of placentrex resulted in delay in
the progression of mucositis, reduction of treatment breaks, regression of pain, and improvement of dysphagia while
leading to no adverse effects (p<0.05). Conclusion: Placentrex appears to be a beneficial therapeutic option for the
management of concurrent chemo-radiation induced acute oral mucositis in oral cancer patients.